Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Combined Company to be leader in ribosomal rna-targeted genetic therapy bringing together complementary platforms. The acquisition also maximizes potential for ELX-02 for cystic fibrosis in phase 2 development.
Lead Product(s): Eukaroyotic ribosomal selective glycoside
Therapeutic Area: Genetic Disease Product Name: ELX-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eloxx Pharmaceuticals
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2021